APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radiopharmaceuticals in Nuclear Medicine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Radiopharmaceuticals in Nuclear Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025197 pages

Choose your research edition.

Industry ResearchRadiopharmaceuticals in Nuclear Medicine Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiopharmaceuticals in Nuclear Medicine Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Radiopharmaceuticals in Nuclear Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiopharmaceuticals in Nuclear Medicine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Radiopharmaceuticals in Nuclear Medicine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Radiopharmaceuticals in Nuclear Medicine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Radiopharmaceuticals in Nuclear Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Radiopharmaceuticals in Nuclear Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Radiopharmaceuticals in Nuclear Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Radiopharmaceuticals in Nuclear Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Radiopharmaceuticals in Nuclear Medicine include Aurobindo Pharma, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Mundipharma and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Radiopharmaceuticals in Nuclear Medicine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Radiopharmaceuticals in Nuclear Medicine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Radiopharmaceuticals in Nuclear Medicine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Radiopharmaceuticals in Nuclear Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.

Radiopharmaceuticals in Nuclear Medicine Segment by Company

Aurobindo Pharma

Bracco Imaging

Cardinal Health

Curium Pharma

GE Healthcare

Jubilant Pharma

Lantheus

Mundipharma

Novartis

SIEMENS

Bayer

Dongcheng

Eli Lilly

China Isotope & Radiation

Radiopharmaceuticals in Nuclear Medicine Segment by Type

Diagnostic Radiopharmaceuticals

Therapy Radiopharmaceuticals

Radiopharmaceuticals in Nuclear Medicine Segment by Application

Oncology

Cardiology

Other

Radiopharmaceuticals in Nuclear Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals in Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals in Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals in Nuclear Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Radiopharmaceuticals in Nuclear Medicine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Radiopharmaceuticals in Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Radiopharmaceuticals in Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Radiopharmaceuticals in Nuclear Medicine Industry Trends Table 2. Radiopharmaceuticals in Nuclear Medicine Industry Drivers Table 3. Radiopharmaceuticals in Nuclear Medicine Industry Opportunities and Challenges Table 4. Radiopharmaceuticals in Nuclear Medicine Industry Restraints Table 5. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers Table 9. Global Radiopharmaceuticals in Nuclear Medicine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Radiopharmaceuticals in Nuclear Medicine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Radiopharmaceuticals in Nuclear Medicine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Radiopharmaceuticals in Nuclear Medicine Manufacturers, Product Type & Application Table 13. Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Radiopharmaceuticals in Nuclear Medicine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Diagnostic Radiopharmaceuticals Table 17. Major Manufacturers of Therapy Radiopharmaceuticals Table 18. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2026) & (K Units) Table 20. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2027-2032) & (K Units) Table 21. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2021-2026) Table 22. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2027-2032) Table 23. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2026) & (K Units) Table 25. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2027-2032) & (K Units) Table 26. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2021-2026) Table 27. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Oncology Table 29. Major Manufacturers of Cardiology Table 30. Major Manufacturers of Other Table 31. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2026) & (K Units) Table 33. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2027-2032) & (K Units) Table 34. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2021-2026) Table 35. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2027-2032) Table 36. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2026) & (K Units) Table 38. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2027-2032) & (K Units) Table 39. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2021-2026) Table 40. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2027-2032) Table 41. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2021-2026) & (K Units) Table 43. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2021-2026) Table 44. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 48. North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 49. Europe Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 51. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 58. Global Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2021-2026) Table 62. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2027-2032) Table 63. Aurobindo Pharma Company Information Table 64. Aurobindo Pharma Business Overview Table 65. Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 67. Aurobindo Pharma Recent Development Table 68. Bracco Imaging Company Information Table 69. Bracco Imaging Business Overview Table 70. Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 72. Bracco Imaging Recent Development Table 73. Cardinal Health Company Information Table 74. Cardinal Health Business Overview Table 75. Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 77. Cardinal Health Recent Development Table 78. Curium Pharma Company Information Table 79. Curium Pharma Business Overview Table 80. Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 82. Curium Pharma Recent Development Table 83. GE Healthcare Company Information Table 84. GE Healthcare Business Overview Table 85. GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 87. GE Healthcare Recent Development Table 88. Jubilant Pharma Company Information Table 89. Jubilant Pharma Business Overview Table 90. Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 92. Jubilant Pharma Recent Development Table 93. Lantheus Company Information Table 94. Lantheus Business Overview Table 95. Lantheus Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 97. Lantheus Recent Development Table 98. Mundipharma Company Information Table 99. Mundipharma Business Overview Table 100. Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 102. Mundipharma Recent Development Table 103. Novartis Company Information Table 104. Novartis Business Overview Table 105. Novartis Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 107. Novartis Recent Development Table 108. SIEMENS Company Information Table 109. SIEMENS Business Overview Table 110. SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 112. SIEMENS Recent Development Table 113. Bayer Company Information Table 114. Bayer Business Overview Table 115. Bayer Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 117. Bayer Recent Development Table 118. Dongcheng Company Information Table 119. Dongcheng Business Overview Table 120. Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 122. Dongcheng Recent Development Table 123. Eli Lilly Company Information Table 124. Eli Lilly Business Overview Table 125. Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 127. Eli Lilly Recent Development Table 128. China Isotope & Radiation Company Information Table 129. China Isotope & Radiation Business Overview Table 130. China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 132. China Isotope & Radiation Recent Development Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Radiopharmaceuticals in Nuclear Medicine Distributors List Table 136. Radiopharmaceuticals in Nuclear Medicine Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Radiopharmaceuticals in Nuclear Medicine Product Image Figure 2. Global Radiopharmaceuticals in Nuclear Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiopharmaceuticals in Nuclear Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Radiopharmaceuticals in Nuclear Medicine Sales (2021-2032) & (K Units) Figure 5. Global Radiopharmaceuticals in Nuclear Medicine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Radiopharmaceuticals in Nuclear Medicine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Diagnostic Radiopharmaceuticals Image Figure 9. Therapy Radiopharmaceuticals Image Figure 10. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2021-2032) Figure 13. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2021-2032) Figure 16. Oncology Image Figure 17. Cardiology Image Figure 18. Other Image Figure 19. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2021-2032) Figure 22. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2021-2032) Figure 25. North America Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2021-2032) Figure 27. U.S. Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2021-2032) Figure 32. Germany Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2021-2032) Figure 39. China Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2021-2032) Figure 47. Brazil Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Radiopharmaceuticals in Nuclear Medicine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Figure 58. North America Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Figure 60. Europe Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Radiopharmaceuticals in Nuclear Medicine Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Radiopharmaceuticals in Nuclear Medicine Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostic Radiopharmaceuticals
  • Therapy Radiopharmaceuticals
Applications
  • Oncology
  • Cardiology
  • Other
Companies covered
  • Aurobindo Pharma
  • Bracco Imaging
  • Cardinal Health
  • Curium Pharma
  • GE Healthcare
  • Jubilant Pharma
  • Lantheus
  • Mundipharma
  • Novartis
  • SIEMENS
  • Bayer
  • Dongcheng
  • Eli Lilly
  • China Isotope & Radiation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Radiopharmaceuticals in Nuclear Medicine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Radiopharmaceuticals in Nuclear Medicine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Radiopharmaceuticals in Nuclear Medicine Market Dynamics
  1. 2.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
  2. 2.2 Radiopharmaceuticals in Nuclear Medicine Industry Drivers
  3. 2.3 Radiopharmaceuticals in Nuclear Medicine Industry Opportunities and Challenges
  4. 2.4 Radiopharmaceuticals in Nuclear Medicine Industry Restraints
3 Radiopharmaceuticals in Nuclear Medicine Market by Manufacturers
  1. 3.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Radiopharmaceuticals in Nuclear Medicine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Radiopharmaceuticals in Nuclear Medicine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Radiopharmaceuticals in Nuclear Medicine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers, Product Type & Application
  7. 3.7 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Radiopharmaceuticals in Nuclear Medicine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Radiopharmaceuticals in Nuclear Medicine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Radiopharmaceuticals in Nuclear Medicine Tier 1, Tier 2, and Tier 3
4 Radiopharmaceuticals in Nuclear Medicine Market by Type
  1. 4.1 Radiopharmaceuticals in Nuclear Medicine Type Introduction
  2. 4.1.1 Diagnostic Radiopharmaceuticals
  3. 4.1.2 Therapy Radiopharmaceuticals
  4. 4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type
  5. 4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2032)
  7. 4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type
  9. 4.3.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2032)
  11. 4.3.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2021-2032)
5 Radiopharmaceuticals in Nuclear Medicine Market by Application
  1. 5.1 Radiopharmaceuticals in Nuclear Medicine Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Cardiology
  4. 5.1.3 Other
  5. 5.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application
  6. 5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2032)
  8. 5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2021-2032)
  9. 5.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application
  10. 5.3.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2032)
  12. 5.3.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2021-2032)
6 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region
  1. 6.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2021-2032)
  3. 6.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2021-2026)
  4. 6.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region
  1. 7.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region
  2. 7.1.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2021-2026)
  4. 7.1.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2027-2032)
  5. 7.1.4 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032)
  8. 7.2.2 North America Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032)
  11. 7.3.2 Europe Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Aurobindo Pharma
  2. 8.1.1 Aurobindo Pharma Company Information
  3. 8.1.2 Aurobindo Pharma Business Overview
  4. 8.1.3 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  6. 8.1.5 Aurobindo Pharma Recent Developments
  7. 8.2 Bracco Imaging
  8. 8.2.1 Bracco Imaging Company Information
  9. 8.2.2 Bracco Imaging Business Overview
  10. 8.2.3 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  12. 8.2.5 Bracco Imaging Recent Developments
  13. 8.3 Cardinal Health
  14. 8.3.1 Cardinal Health Company Information
  15. 8.3.2 Cardinal Health Business Overview
  16. 8.3.3 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  18. 8.3.5 Cardinal Health Recent Developments
  19. 8.4 Curium Pharma
  20. 8.4.1 Curium Pharma Company Information
  21. 8.4.2 Curium Pharma Business Overview
  22. 8.4.3 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  24. 8.4.5 Curium Pharma Recent Developments
  25. 8.5 GE Healthcare
  26. 8.5.1 GE Healthcare Company Information
  27. 8.5.2 GE Healthcare Business Overview
  28. 8.5.3 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  30. 8.5.5 GE Healthcare Recent Developments
  31. 8.6 Jubilant Pharma
  32. 8.6.1 Jubilant Pharma Company Information
  33. 8.6.2 Jubilant Pharma Business Overview
  34. 8.6.3 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  36. 8.6.5 Jubilant Pharma Recent Developments
  37. 8.7 Lantheus
  38. 8.7.1 Lantheus Company Information
  39. 8.7.2 Lantheus Business Overview
  40. 8.7.3 Lantheus Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  42. 8.7.5 Lantheus Recent Developments
  43. 8.8 Mundipharma
  44. 8.8.1 Mundipharma Company Information
  45. 8.8.2 Mundipharma Business Overview
  46. 8.8.3 Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  48. 8.8.5 Mundipharma Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 SIEMENS
  56. 8.10.1 SIEMENS Company Information
  57. 8.10.2 SIEMENS Business Overview
  58. 8.10.3 SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  60. 8.10.5 SIEMENS Recent Developments
  61. 8.11 Bayer
  62. 8.11.1 Bayer Company Information
  63. 8.11.2 Bayer Business Overview
  64. 8.11.3 Bayer Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  66. 8.11.5 Bayer Recent Developments
  67. 8.12 Dongcheng
  68. 8.12.1 Dongcheng Company Information
  69. 8.12.2 Dongcheng Business Overview
  70. 8.12.3 Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  72. 8.12.5 Dongcheng Recent Developments
  73. 8.13 Eli Lilly
  74. 8.13.1 Eli Lilly Company Information
  75. 8.13.2 Eli Lilly Business Overview
  76. 8.13.3 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  78. 8.13.5 Eli Lilly Recent Developments
  79. 8.14 China Isotope & Radiation
  80. 8.14.1 China Isotope & Radiation Company Information
  81. 8.14.2 China Isotope & Radiation Business Overview
  82. 8.14.3 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  84. 8.14.5 China Isotope & Radiation Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Radiopharmaceuticals in Nuclear Medicine Value Chain Analysis
  2. 9.1.1 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Radiopharmaceuticals in Nuclear Medicine Production Mode & Process
  6. 9.2 Radiopharmaceuticals in Nuclear Medicine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Radiopharmaceuticals in Nuclear Medicine Distributors
  9. 9.2.3 Radiopharmaceuticals in Nuclear Medicine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst